Work

Daidzein derivative daid002 inhibits glioblastoma growth via disrupting the interaction between moesin and CD44

Year: 2018

Type: article

Abstract: // Xin Zhang 1 , Xiuting Liu 1 , Jinghui Zhang 1 , Wei Zhou 1 , Jinrong Lu 2 , Qing Wang 3 and Rong Hu 1 1 State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing, 210009, China 2 Department of Organic Chemistry, China Pharmaceutical University, Jiangsu, Nanjing, 210009, China 3 Department of Neurosurgery, Wuxi Second Hospital Affiliated Nanjing Medical University, Jiangsu, Wuxi 214002, China Correspondence to: Qing Wang, email: [email protected] Rong Hu, email: [email protected] Keywords: glioblastoma; daid002; moesin; CD44 Received: August 29, 2017 Accepted: December 01, 2017 Published: January 11, 2018 ABSTRACT Glioblastoma multiforme is a fatal brain tumor with very limited therapeutic options. Recently, an ezrin-radixin-moesin family protein, moesin, is reported to be positively correlated with higher grade of glioblastoma. Here, we reported that daid002, a novel daidzein derivative, inhibited glioblastoma growth and induced G0/G1 phase arrest. Daid002 decreased moesin phosphorylation through restraint of the direct interaction between moesin and CD44 on the cell membrane and reduced cyclin D1 expression via regulating nuclear translocation of β-catenin. In vivo , daid002 exerted a significant inhibition on glioblastoma growth through CD44/moesin signaling. Our findings established daid002 as an anti-glioblastoma agent by targeting CD44/moesin.

Source: Oncotarget

DOI: 10.18632/oncotarget.24166